Who is the sponsor?
Thrombogenics
Who are the patients?
Participants with focal vitreomacular traction . The participating doctor will evaluate the patient to determine his/her eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.
How long is the trial?
All participants will be monitored monthly for 6 months and will undergo a complete eye examination, ultrasound testing, and optical coherence tomography scans at each visit.
How many subjects were enrolled?
326 patients across US and International sites.
Is the enrollment still open?
The trial has been completed.
What is this study investigating?
To evaluate the safety and efficacy of intravitreal microplasmin 125 microgram dose to determine if microplasmin can help relieve the traction or tension between the vitreous and retina and forego the need for invasive surgery.
How is the treatment administered?
A small dose of microplasmin (125 micrograms) or placebo vehicle (contains same liquid but without microplasmin) administered as an injection into eye.